USD 2.11
(-10.21%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 7.06 Million USD | -40.36% |
2022 | 11.85 Million USD | 12.09% |
2021 | 10.57 Million USD | 12.07% |
2020 | 9.43 Million USD | 47.51% |
2019 | 6.39 Million USD | 13.0% |
2018 | 5.65 Million USD | -28.73% |
2017 | 7.94 Million USD | -14.55% |
2016 | 9.29 Million USD | -2.5% |
2015 | 9.53 Million USD | -37.7% |
2014 | 15.3 Million USD | -38.76% |
2013 | 24.98 Million USD | 21437.64% |
2012 | 116.01 Thousand USD | -87.19% |
2011 | 905.33 Thousand USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 12.45 Million USD | 76.19% |
2024 Q2 | 12.13 Million USD | -2.55% |
2023 Q2 | 8.97 Million USD | -10.55% |
2023 FY | 7.06 Million USD | -40.36% |
2023 Q4 | 7.06 Million USD | -9.99% |
2023 Q3 | 7.85 Million USD | -12.55% |
2023 Q1 | 10.03 Million USD | -15.29% |
2022 Q2 | 14.4 Million USD | 59.58% |
2022 FY | 11.85 Million USD | 12.09% |
2022 Q4 | 11.85 Million USD | -11.63% |
2022 Q1 | 9.02 Million USD | -14.63% |
2022 Q3 | 13.41 Million USD | -6.9% |
2021 Q4 | 10.57 Million USD | -9.24% |
2021 Q3 | 11.64 Million USD | -33.65% |
2021 Q2 | 17.55 Million USD | -9.01% |
2021 FY | 10.57 Million USD | 12.07% |
2021 Q1 | 19.29 Million USD | 104.54% |
2020 Q3 | 6.75 Million USD | -18.34% |
2020 Q1 | 4.63 Million USD | -27.48% |
2020 Q2 | 8.26 Million USD | 78.25% |
2020 Q4 | 9.43 Million USD | 39.75% |
2020 FY | 9.43 Million USD | 47.51% |
2019 Q3 | 7.32 Million USD | -3.98% |
2019 Q2 | 7.63 Million USD | 74.91% |
2019 Q1 | 4.36 Million USD | -22.92% |
2019 FY | 6.39 Million USD | 13.0% |
2019 Q4 | 6.39 Million USD | -12.72% |
2018 FY | 5.65 Million USD | -28.73% |
2018 Q1 | 5.58 Million USD | -29.68% |
2018 Q4 | 5.65 Million USD | -19.36% |
2018 Q3 | 7.01 Million USD | 5.92% |
2018 Q2 | 6.62 Million USD | 18.65% |
2017 Q3 | 10.75 Million USD | -18.22% |
2017 Q2 | 13.15 Million USD | -11.34% |
2017 FY | 7.94 Million USD | -14.55% |
2017 Q4 | 7.94 Million USD | -26.19% |
2017 Q1 | 14.83 Million USD | 59.65% |
2016 Q4 | 9.29 Million USD | -14.05% |
2016 FY | 9.29 Million USD | -2.5% |
2016 Q2 | 4.63 Million USD | -32.54% |
2016 Q3 | 10.81 Million USD | 133.22% |
2016 Q1 | 6.87 Million USD | -27.9% |
2015 Q1 | 12.62 Million USD | -17.52% |
2015 FY | 9.53 Million USD | -37.7% |
2015 Q4 | 9.53 Million USD | -18.41% |
2015 Q3 | 11.68 Million USD | 10.13% |
2015 Q2 | 10.6 Million USD | -15.95% |
2014 Q1 | 22.56 Million USD | -9.68% |
2014 Q2 | 17.02 Million USD | -24.57% |
2014 FY | 15.3 Million USD | -38.76% |
2014 Q4 | 15.3 Million USD | 14.27% |
2014 Q3 | 13.39 Million USD | -21.34% |
2013 Q4 | 24.98 Million USD | 5.26% |
2013 Q1 | 1.68 Million USD | 1348.13% |
2013 Q2 | 1.79 Million USD | 6.73% |
2013 Q3 | 23.73 Million USD | 1223.89% |
2013 FY | 24.98 Million USD | 21437.64% |
2012 FY | 116.01 Thousand USD | -87.19% |
2012 Q4 | 116.01 Thousand USD | 0.0% |
2011 FY | 905.33 Thousand USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ANI Pharmaceuticals, Inc. | 904.42 Million USD | 99.218% |
Aquestive Therapeutics, Inc. | 57.41 Million USD | 87.689% |
Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 99.382% |
Dynavax Technologies Corporation | 997.09 Million USD | 99.291% |
Esperion Therapeutics, Inc. | 205.79 Million USD | 96.565% |
Cosmos Health Inc. | 66.29 Million USD | 89.338% |
Pacira BioSciences, Inc. | 1.57 Billion USD | 99.551% |
PainReform Ltd. | 9.93 Million USD | 28.816% |
Sunshine Biopharma, Inc. | 27.34 Million USD | 74.152% |
Sunshine Biopharma, Inc. | 27.34 Million USD | 74.152% |
SCYNEXIS, Inc. | 128.41 Million USD | 94.495% |
Safety Shot Inc | 12.7 Million USD | 44.382% |
China SXT Pharmaceuticals, Inc. | 23.12 Million USD | 69.436% |
Alpha Teknova, Inc. | 128.58 Million USD | 94.503% |
Embecta Corp. | 1.21 Billion USD | 99.418% |
Bright Green Corporation | 17.4 Million USD | 59.383% |
Intra-Cellular Therapies, Inc. | 728.29 Million USD | 99.029% |
Journey Medical Corporation | 76.84 Million USD | 90.802% |
Procaps Group, S.A. | 460.18 Million USD | 98.464% |
Theratechnologies Inc. | 77.76 Million USD | 90.911% |
Harrow Health, Inc. | 311.75 Million USD | 97.733% |
Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | 52.538% |
Biofrontera Inc. | 27.93 Million USD | 74.694% |
DURECT Corporation | 45.18 Million USD | 84.358% |
Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 99.498% |
Cronos Group Inc. | 1.13 Billion USD | 99.377% |
OptiNose, Inc. | 107.72 Million USD | 93.439% |
Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 98.499% |
Kala Pharmaceuticals, Inc. | 55.94 Million USD | 87.366% |
RedHill Biopharma Ltd. | 23.04 Million USD | 69.33% |
Organogenesis Holdings Inc. | 460.02 Million USD | 98.463% |
Guardion Health Sciences, Inc. | 11.91 Million USD | 40.691% |
Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 91.356% |
Radius Health, Inc. | 1.71 Billion USD | 99.588% |
Universe Pharmaceuticals INC | 53.28 Million USD | 86.735% |
ProPhase Labs, Inc. | 91.92 Million USD | 92.311% |
Phibro Animal Health Corporation | 982.18 Million USD | 99.28% |
Procaps Group S.A. | 460.18 Million USD | 98.464% |
Alvotech | 950.09 Million USD | 99.256% |
TherapeuticsMD, Inc. | 43.3 Million USD | 83.679% |
Viatris Inc. | 47.68 Billion USD | 99.985% |
Rockwell Medical, Inc. | 52.17 Million USD | 86.452% |
Aytu BioPharma, Inc. | 118.09 Million USD | 94.015% |
SIGA Technologies, Inc. | 254.83 Million USD | 97.226% |
Tilray Brands, Inc. | 4.33 Billion USD | 99.837% |
Lifecore Biomedical, Inc. | 273.7 Million USD | 97.417% |
Shineco, Inc. | 84.17 Million USD | 91.603% |
PetIQ, Inc. | 868.22 Million USD | 99.186% |
Regencell Bioscience Holdings Limited | 8.43 Million USD | 16.232% |
Incannex Healthcare Limited | 17.04 Million USD | 58.535% |
Neurocrine Biosciences, Inc. | 3.25 Billion USD | 99.783% |
Alimera Sciences, Inc. | 153.52 Million USD | 95.396% |
Silver Spike Investment Corp. | 88.57 Million USD | 92.02% |
Assertio Holdings, Inc. | 286.41 Million USD | 97.532% |
Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -18.764% |
Petros Pharmaceuticals, Inc. | 33.79 Million USD | 79.085% |
Clever Leaves Holdings Inc. | 31.24 Million USD | 77.376% |
Cyclo Therapeutics, Inc. | 13.24 Million USD | 46.643% |
Avadel Pharmaceuticals plc | 261.12 Million USD | 97.293% |
Hempacco Co., Inc. | 18.04 Million USD | 60.824% |
Talphera, Inc. | 20.39 Million USD | 65.342% |
Alvotech | 950.09 Million USD | 99.256% |
Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 98.26% |
Lantheus Holdings, Inc. | 1.65 Billion USD | 99.572% |
Currenc Group, Inc. | 141.49 Million USD | 95.004% |
Kamada Ltd. | 351.96 Million USD | 97.992% |
Indivior PLC | 1.95 Billion USD | 99.638% |
Flora Growth Corp. | 23.62 Million USD | 70.081% |
Cyclo Therapeutics, Inc. | 13.24 Million USD | 46.643% |
Evolus, Inc. | 188.99 Million USD | 96.26% |
HUTCHMED (China) Limited | 1.27 Billion USD | 99.448% |
Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 99.533% |
Akanda Corp. | 8.83 Million USD | 20.039% |